(Alliance News) - Hutchmed China Ltd on Wednesday said the results from its SACHI phase-three lung cancer trial have been published in medical journal the Lancet. Read More
(Alliance News) - Stock prices in London were mixed at midday on Wednesday, as gains among miners lifted the FTSE 100. Read More
(Alliance News) - Polar Capital Global Healthcare Trust PLC on Wednesday said demand for healthcare products remains robust as it outperformed its benchmark. Read More
(Alliance News) - UK Business Secretary Peter Kyle is set to tell the heads of top firms that he will "fight tooth and nail" to achieve US levels of economic growth. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday: Read More
(Alliance News) - Blue chips continued their strong start to the year on Tuesday with the FTSE 100 hitting a new record led by gains in retailer Next and drug stocks, GSK and AstraZeneca. Read More
(Alliance News) - AstraZeneca PLC on Tuesday said a Saphnelo self-administration Thlip-SC trial demonstrated statistically significant and clinically meaningful reduction in systemic lupus erythematosus disease activity. Read More
(Alliance News) - Hutchmed China Ltd on Tuesday said Chinese regulators have accepted and granted priority review to its new drug application for savolitinib to treat certain patients with advanced gastric cancer, marking another regulatory step forward for the targeted therapy. Read More
(Alliance News) - The FTSE 100 drifted lower on Wednesday in lacklustre trading ahead of the Christmas break, although a chunky disposal by BP brought some life to proceedings. Read More
(Alliance News) - Stock prices in London opened modestly lower on Wednesday, during a shortened trading session ahead of the Christmas holiday break. Read More
(Alliance News) - AstraZeneca PLC on Monday said a phase three trial in a potential treatment for a form of non-small cell lung cancer failed to meet a key aim, while its early breast cancer drug has been granted a breakthrough therapy designation in the US. Read More
(Alliance News) - Harbour Energy has struck a deal to deliver on a "long-standing ambition", while AstraZeneca reports a drug failed to meet its primary endpoint in a phase three trial, while another got breakthrough therapy designation in the US. Read More
(Alliance News) - Daiichi Sankyo Co Ltd on Thursday said the EU has validated an application for Datroway as a first-line treatment for patients with metastatic triple negative breast cancer who are not candidates for immunotherapy. Read More
(Alliance News) - AstraZeneca PLC on Tuesday said its drug Saphnelo, or anifrolumab, has been approved in the European Union as a new pre-filled pen for systemic lupus erythematosus. Read More
(Alliance News) - AstraZeneca PLC on Monday said enhertu plus pertuzumab has been approved in the US as a first-line treatment of patients with HER2-positive metastatic breast cancer. Read More
(Alliance News) - Outgoing GSK PLC Chief Executive Officer Emma Walmsley has said the US is the best place to invest, in the latest blow to Britain's pharmaceutical sector, after a raft of drugs firms have scrapped or paused plans to invest in the UK. Read More
(Alliance News) - Hutchmed China Ltd on Monday said several of its oncology medicines will continue to be reimbursed under China's national insurance scheme next year, while one of its newer cancer drugs has secured a place on the country's first-ever commercial insurance drug list. Read More
(Alliance News) - The following London-listed shares received analyst recommendations on Monday morning and on Friday: Read More
(Alliance News) - A deal that gives the US zero tariffs on its imports of UK pharmaceuticals in return for the National Health Service raising spending on medicines will cost around GBP1 billion, Downing Street has said. Read More
(Alliance News) - AstraZeneca PLC on Tuesday announced that its new drug application under US Food & Drug Administration priority review for its selective inhibitor baxdrostat for certain patients has been accepted. Read More